Overview

Price chart · mood · technical indicators

NNNN

Anbio Biotechnology Class A Ordinary Sharesstock Healthcare

Medical Instruments & Supplies

$29.98356.32%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$6.24$55.65

Current: $29.98

Market Comparison

vs Healthcare Sector & Medical Instruments & Supplies Industry

NNNN

+356.32%

1Y Performance

Healthcare

Sector 1Y

Medical Instruments & Supplies

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio192.67

EPS (TTM)$0.152.8% YoY

Profit margin74.1%HEALTHCARE

Market cap$1.27BSmall cap

Valuation

Forward P/E: —
PEG ratio: —
P/B: 42.06
P/S (TTM): 146.70
EV/EBITDA: 217.86

Profitability & growth

ROE (TTM): 27.1%
Operating margin: 59.1%
Revenue growth YoY: 73.9%
Dividend yield: —
Beta: —

Last earnings

Dec 30, 2025 · Estimate $0.00 · Reported $0.09

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

28 articles · sorted by date

Page 1 of 2 · 28 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Anbio Biotechnology Class A Ordinary Shares

Company profile

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.

Classification

Sector: Healthcare
Industry: Medical Instruments & Supplies
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: WILHELM GUTBROD STR 21B, FRANKFURT AM MAIN, GERMANY
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$1.27B

Shares outstanding$43.9M

52W high$55.65

52W low$6.24

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

NNNN

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

Free cash flow per share of Anbio Biotechnology Class A – FWB:N3B

Anbio Biotechnology Calls May 15 Shareholder Votes on Sweeping Capital and Governance Overhaul

Anbio Biotechnology (NNNN) files 20-F/A to mark well-known seasoned issuer

Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)

Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review

Financial Analysis: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)

Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head to Head Contrast

Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Forecast & Price Prediction 2026–2030

Critical Comparison: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)

Comparing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)

Anbio Biotechnology Replaces Auditor to Safeguard 2025 Reporting Timeline

Anbio Biotechnology Stock Price Today | NASDAQ: NNNN Live

Anbio Biotechnology Class A Shares Surge After Volatility Pause

Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026

Anbio Biotechnology Strengthens Board Oversight With Appointment of Michael Zhang as Audit Committee Chair

Anbio Biotechnology Posts Higher Margins and Profits Despite Revenue Dip in First Half of 2025

Anbio Biotechnology Posts Higher Margins and Profits Despite Revenue Dip in First Half of 2025

Year-End Review | The 2025 US IPO Gainers List is Out! Anbio Biotechnology Soars Over 570%, 'First Stablecoin Stock' Circle Surges More Than 180%

Why Anbio Biotechnology’s Stock is Tumbling - TipRanks

NNNN Stock Price, News & Analysis

About Anbio Biotechnology Class A Ordinary Shares

Classification

Company profile

NNNN

Market Comparison

NNNN Market Analysis

Overview

NNNN

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

Free cash flow per share of Anbio Biotechnology Class A – FWB:N3B

Anbio Biotechnology Calls May 15 Shareholder Votes on Sweeping Capital and Governance Overhaul

Anbio Biotechnology (NNNN) files 20-F/A to mark well-known seasoned issuer

Head-To-Head Analysis: Oncocyte (NASDAQ:IMDX) & Anbio Biotechnology (NASDAQ:NNNN)

Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head-To-Head Review

Financial Analysis: Oncocyte (NASDAQ:IMDX) and Anbio Biotechnology (NASDAQ:NNNN)

Oncocyte (NASDAQ:IMDX) versus Anbio Biotechnology (NASDAQ:NNNN) Head to Head Contrast

Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Forecast & Price Prediction 2026–2030

Critical Comparison: Oncocyte (NASDAQ:IMDX) vs. Anbio Biotechnology (NASDAQ:NNNN)

Comparing Anbio Biotechnology (NASDAQ:NNNN) & Oncocyte (NASDAQ:IMDX)

Anbio Biotechnology Replaces Auditor to Safeguard 2025 Reporting Timeline

Anbio Biotechnology Stock Price Today | NASDAQ: NNNN Live

Anbio Biotechnology Class A Shares Surge After Volatility Pause

Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026

Anbio Biotechnology Strengthens Board Oversight With Appointment of Michael Zhang as Audit Committee Chair

Anbio Biotechnology Posts Higher Margins and Profits Despite Revenue Dip in First Half of 2025

Anbio Biotechnology Posts Higher Margins and Profits Despite Revenue Dip in First Half of 2025

Year-End Review | The 2025 US IPO Gainers List is Out! Anbio Biotechnology Soars Over 570%, 'First Stablecoin Stock' Circle Surges More Than 180%

Why Anbio Biotechnology’s Stock is Tumbling - TipRanks

NNNN Stock Price, News & Analysis

About Anbio Biotechnology Class A Ordinary Shares

Classification

Company profile

NNNN

Market Comparison